FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Mottiwala Aziz (Last) (First) (Middle) C/O TARSUS PHARMACEUTICALS, INC.						Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS] Inc. [TARS] 3. Date of Earliest Transaction (Month/Day/Year) 08/24/2022									S. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Commercial Officer					wner	
15440 L. (Street) IRVINE (City)	C		92618 (Zip)	160	4. If Amendment, Date of Original Filed (Month/Day/Year)										i. Indivine)						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date				2. Transa Date (Month/D	Execution Date,			Code (Instr. 5)						Securities Fe Beneficially (E		Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										Code	v	Amount (A) or (D)		Price	Transaction		tion(s)	n(s) d 4)		(111501.4)	
Common Stock 08,			08/24	2022				M		4,410	16 A		\$10).99	55,814 ⁽¹⁾			D			
Common Stock 08/24			2022			M		772 A \$		\$0	.45	56,586			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed 4 Date, 1	ransaction code (Instr.		5. Number 6.		6. I	5. Date Exercisal Expiration Date Month/Day/Year		ble and	7. Title and Amount of Securities Underlying Derivative Secui (Instr. 3 and 4)		Securit	8. De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				C	Code \	,	(A)	(D)	Da Ex	ite ercisabl		xpiration ate	Title		Amour or Numbe of Shares	er					
Employee Stock Option (right to buy)	\$10.99	08/24/2022			М			4,416		(2)	0	9/24/2030		nmon ock	4,416	5 :	\$10.99	10,573	3	D	
Employee Stock Option	\$0.45	08/24/2022			М			772		(3)	0	9/13/2028		nmon ock	772		\$0.45	0		D	

Explanation of Responses:

- 1. Includes 470 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 725 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
- 2. Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
- 3. Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments

Remarks:

/s/ Leonard M. Greenstein, Attorney-in-Fact ** Signature of Reporting Person

08/26/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.